Ceapro Inc V.CZO

RE:VCAM-1 and avenanthramide:

[prophetoffactz]

Basically, based on the VCAM-1 reduction with the smoothy at 90mg avenanthramide, CZO's 120 mg pill that could be cleared in the first weak of March could make this a product. This is also over 11X higher than the per cookie dose in the exercise inflammation study.  

prophetoffactz wrote: 90 mg per day of avenanthramide in a smoothy lowered VCAM-1 10-13% in this study of obese adults.

AvenanthramideEnriched Oats Have an AntiInflammatory Action: A Pilot Clinical Trial - McKay - 2015 - The FASEB Journal - Wiley Online Library

CZO's avenanthramide pill trial has passed 30 mg and 60 mg and 120 mg will be completed in the first week of March. CZO will then be 33% above the daily dose in the smoothy and with a pharma-grade avenanthramide. It will keep doubling the dose and then add a second dose in a day. CZO reported on Friday about its results to date: "These results are very promising given that the higher the dose without safety concerns, the larger the potential for extending to various inflammation-based diseases."

I asked Bing what treatment options open up the lower you can drive VCAM-1...

VCAM-1 (Vascular Cell Adhesion Molecule 1) is a protein that plays a crucial role in inflammation and immune responses. It is expressed on the surface of endothelial cells and is involved in leukocyte adhesion during inflammation. Lowering VCAM-1 levels can have therapeutic benefits, particularly in conditions related to chronic inflammation and cardiovascular health.

Here’s a breakdown of the potential therapeutic benefits at different levels of VCAM-1 reduction:

1. 10-20% Reduction:

   • Anti-Inflammatory Effects: Even a modest reduction in VCAM-1 levels can lead to decreased leukocyte adhesion and reduced inflammation. This may be beneficial in conditions like atherosclerosis, where inflammation contributes to plaque formation in blood vessels.

2. 20-30% Reduction:

   • Cardiovascular Protection: Further lowering VCAM-1 levels can improve endothelial function and reduce the risk of cardiovascular events. Improved endothelial function promotes better blood flow and reduces the risk of clot formation.
   • Reduced Atherosclerotic Plaque Formation: Lower VCAM-1 levels may slow down the progression of atherosclerosis by inhibiting leukocyte recruitment to vessel walls.

3. 30-40% Reduction:

   • Endothelial Health: Significant VCAM-1 reduction can enhance endothelial health, leading to improved vasodilation and reduced blood pressure.
   • Potential Impact on Autoimmune Diseases: VCAM-1 is implicated in autoimmune conditions. Lowering it substantially may benefit patients with autoimmune disorders.

4. Higher Reduction (>40%):

   • Therapeutic Intensity: At this level, the focus shifts from prevention to active treatment. VCAM-1 reduction becomes a targeted therapy for specific diseases.
   • Immune Modulation: Extremely low VCAM-1 levels could potentially affect immune responses. While this might be beneficial in certain situations, it could also compromise immune surveillance.

Can You Lower VCAM-1 Too Much? Yes, it’s possible to lower VCAM-1 excessively. While reducing VCAM-1 has benefits, it’s essential to maintain a balance. Overly low levels could lead to unintended consequences:

• Impaired immune responses: VCAM-1 is involved in immune cell trafficking, and too little of it might hinder immune surveillance.
• Increased bleeding risk: VCAM-1 plays a role in platelet adhesion, and extremely low levels could affect clotting mechanisms.

In summary, achieving a meaningful therapeutic benefit involves striking the right balance—reducing VCAM-1 enough to mitigate inflammation and cardiovascular risks without compromising overall health. Consultation with a healthcare professional is crucial for personalized guidance based on individual health conditions.

--------